Cyclin-dependent kinase inhibitors closer to market launch? - Wikidata - wikimedia - TriplyDB

Cyclin-dependent kinase inhibitors closer to market launch?

Cyclin-dependent kinase inhibitors closer to market launch?

http://www.wikidata.org/entity/Q38100203

about

Maintaining Genome Stability in Defiance of Mitotic DNA Damage CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177.Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics Cyclin-dependent kinase inhibitors as marketed anticancer drugs: where are we now? A short survey.The centrosome: a prospective entrant in cancer therapy.Recent advances in the identification of Tat-mediated transactivation inhibitors: progressing toward a functional cure of HIV.Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study.Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models.Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines.SAR study on N2,N4-disubstituted pyrimidine-2,4-diamines as effective CDK2/CDK9 inhibitors and antiproliferative agents.

P2860

Q26738970-2DCE53FB-D11B-41DC-BCE5-73195AF6A969 Q33864755-B1EF21F2-25C6-4C64-8F02-770219446DC5 Q34687067-50D0871C-D1C4-4884-B705-EE54E5FD205B Q36186117-B7771A04-A448-421E-ACA7-5057CCBFB843 Q38248633-2440ED09-2821-499F-943D-51E2BF2FEBDB Q38383234-C96EEA09-31EB-4EA7-962E-FEFD931DD0B1 Q38757713-1A830493-9B46-40E9-A28D-4080C6C97FB9 Q38997714-F75C4A09-58DF-4A5E-B207-B0DF8C0DE8FE Q40989800-B9423759-8076-4439-9EFC-0D05B5AC7AE0 Q48124327-82959AF9-1B3B-4088-B853-F5DB8630684F Q52717605-1A1923EA-392E-4D5C-B269-D7523AEC5496

P2860

Cyclin-dependent kinase inhibitors closer to market launch?

http://www.wikidata.org/entity/Q38100203

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Cyclin-dependent kinase inhibitors closer to market launch?

@en

type

label

Cyclin-dependent kinase inhibitors closer to market launch?

@en

prefLabel

Cyclin-dependent kinase inhibitors closer to market launch?

@en

P1433

Q38100203-B4C2CA01-8174-4C4D-A31A-59E951635AB7

P1476

Q38100203-D9484B38-C4F9-4313-96EC-D1D4F12424B9

P2093

Q38100203-1BAA1FC3-303B-43F5-B539-8E028A0EF055

Q38100203-4008A6ED-2D04-40DB-B8FD-45A55796BE63

Q38100203-7963FA98-8CE1-47F6-A1F9-19EE6DC1324D

Q38100203-C5CBC517-ADCD-47F4-A8F3-BCEF3A002368

P2860

Q38100203-0EEDB44D-1AE3-4A6C-8C86-6EB5E4E369AA

Q38100203-1587EF09-C55B-48D8-8C34-DCE8912CBFEE

Q38100203-197BE8C0-2D1A-4E3A-864F-2FED61772531

Q38100203-1D434B75-106C-4A75-9197-4FBDD18EA5DE

Q38100203-1E5E0F8A-6593-40C1-8929-F63082112EA2

Q38100203-26AAA52D-4399-49AB-89F0-3C9F45E863ED

Q38100203-2EB673D3-1C28-4DF2-BF67-8A4750F13A73

Q38100203-3B6EC706-6BDC-41D4-BE6C-DC413DA8C003

Q38100203-3E0A06FD-2466-4F0E-A900-EF2E72DB1C8E

Q38100203-41854951-5A9A-497E-9BD4-7FAE9D847790

P304

Q38100203-751A844A-E5CF-4AF7-949D-E85554CD863A

P31

Q38100203-E77A0532-D501-4340-BF08-91EFFA015B5F

P356

Q38100203-FE21F1B6-7AC8-47F6-80B9-B5A7ED27CECF

P407

Q38100203-E467A691-720E-4D60-8437-B77144BCBC7D

P433

Q38100203-AB81CD57-E47A-43B3-87E6-6DE0F3D7DB78

P478

Q38100203-8C3DDA89-A35D-484C-97B3-D1FDBF4BF408

P50

Q38100203-0832276A-C421-425B-A751-6CC3D9C6AE02

P577

Q38100203-3F7DE88C-A2F1-4782-AB68-4E2AD14568DA

P5875

Q38100203-D61968DF-4BA5-4FB1-B6AF-E7B34FE2444E

P698

Q38100203-D84638DD-6ECD-49D8-BE7D-BCB45EBA0A81

P356

13543776.2013.789861

P1433

Expert Opinion on Therapeutic Patents

P1476

Cyclin-dependent kinase inhibitors closer to market launch?

@en

P2093

Hervé Galons

http://www.w3.org/2001/XMLSchema#string

Laurent Meijer

http://www.w3.org/2001/XMLSchema#string

Nassima Oumata

http://www.w3.org/2001/XMLSchema#string

Olfa Gloulou

http://www.w3.org/2001/XMLSchema#string

P2860

Cell cycle, CDKs and cancer: a changing paradigm

Apoptosis is essential for neutrophil functional shutdown and determines tissue damage in experimental pneumococcal meningitis

Structure-guided discovery of cyclin-dependent kinase inhibitors

CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases

Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity

Discovery of a Potential Allosteric Ligand Binding Site in CDK2

CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.

Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models

Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry.

P304

945-963

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543776.2013.789861

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-04-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236249219

http://www.w3.org/2001/XMLSchema#string

P698

23600454

http://www.w3.org/2001/XMLSchema#string